UnitedHealth Group's third-quarter 2024 earnings call highlighted several key points that will likely influence the stock's short-term performance:

1. **Strong Revenue and Operational Performance**: The company reported a 9% year-over-year revenue growth, driven by expansions in Optum and UnitedHealthcare, which is a positive indicator of its market strength and execution capabilities[1][3][5].

2. **Challenges and Headwinds**: Despite the strong performance, the company faces several challenges, including the impact of CMS Medicare rate cuts, state-driven Medicaid member redeterminations, and increased specialty drug prescriptions. These factors have contributed to higher-than-expected costs and are anticipated to continue into 2025[1][3].

3. **Guidance and Outlook**: The 2024 adjusted earnings outlook was narrowed to $27.50-$27.75 per share, reflecting the business disruption costs and care pattern impacts. For 2025, the company is taking a conservative approach due to external pressures, with an initial earnings guidance around $30 per share, which is below the typical 13%-16% growth target[1][3].

4. **Investment in Future Growth**: UnitedHealth Group remains committed to investing in value-based care, technology modernization, and consumer experience improvement, which are seen as key growth drivers for the long term. This investment, however, may temporarily offset some of the short-term earnings growth due to the ongoing external pressures[1][3].

Given these points, the stock is likely to experience some short-term pressure due to the conservative 2025 guidance and the ongoing challenges, despite the strong operational performance and long-term growth potential.

**Rating: -1**